ImmunityBio, Inc.IBRXNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank100
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Latest
22.06%
↑ 165% vs avg
Percentile
P100
Near historical high
Streak
4 yr
Consecutive growthAccelerating
Average
-33.78%
Historical baseline
PeriodValue
202522.06%
2024-6.67%
2023-8.67%
2022-22.99%
2021-59.80%
2020-12.90%
2019-139.99%
2018-29.93%
2017-26.40%
2016-52.51%